Tenderwize
Retour à la recherche

Open House Original Rebate Contracts 2026-05 Alectinib

Techniker Krankenkasse·Hamburg, Germany·Deadline Jul 30, 2028 · 704 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open-House-Originale-Rabattverträge 2026-05 Alectinib

60/100

Score d'opportunité

PromisingLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

60 / 100

Complexité

30 / 100

Facteurs de risque

The procedure is explicitly not a public procurement under EU directives; legal recourse is via social courts, not proc...

No estimated contract value or framework maximum is provided. Without this, it is impossible to assess the financial at...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Strong opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Jul 2028
  • Conclusion of pharmaceutical rebate contracts (Rabattverträge) for the active substance Alectinib
  • Non-exclusive, open to all eligible pharmaceutical entrepreneurs
Afficher le résumé complet

This is an Open-House procedure (not a traditional public procurement) by Techniker Krankenkasse and other German health insurers for rebate contracts (Rabattverträge) under § 130c SGB V for the active substance Alectinib. Any eligible pharmaceutical entrepreneur can join at any time during the contract period (max 24 months starting 01.08.2026, ending 31.07.2028). No estimated value is provided. The procedure is non-exclusive with uniform conditions. Submission is via email or postal mail at any time. The tender documents are available online but were not analyzed. Notably, the procedure is not subject to standard procurement law; disputes go to social courts.

Risques

The procedure is explicitly not a public procurement under EU directives; legal recourse is via social courts, not proc...

No estimated contract value or framework maximum is provided. Without this, it is impossible to assess the financial at...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur (pharmazeutischer Unternehmer) as defined in §4 Abs.18 AMG
  • Must hold a valid marketing authorization for the medicinal product containing Alectinib
  • Must have seat in Germany, EU, or EEA

Les exigences peuvent être incomplètes.

Acheteur

Localisation

Hamburg, DEU

Identifiant

992-80116-93

Activité

Health

Lots (1)

LOT-0001

Open House Original Rebate Contracts 2026-05 Alectinib

Conclusion of pharmaceutical rebate contracts for the active substance Alectinib under an Open-House procedure. The contract duration is up to 24 months, starting 01.08.2026, with automatic termination upon patent expiry. Participation is possible throughout the contract period.

SuppliesEU fundedElectronic submission

Localisation

DE600, Germany

Durée

Jul 2026 - Jul 2028

Catégorie

Pharmaceutical products

Date limite

Deadline Jul 30, 2028

Détails de la procédure

Date de publication
01 Jul 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
455118-2026

Documents (1)

Document de consultation 1

Appels d'offres similaires

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3